- Winlevi is a first-in-class topical androgen receptor inhibitor approved by the US FDA for the treatment of acne in patients (age ≥12 yrs.) with a new mechanism of action (MOA) after ~ 40 yrs.
- Result: Winlevi demonstrated treatment success and reductions in acne lesions and was well tolerated when used q2w (in pivotal clinical trials). Additionally, the most frequently observed local skin reaction was mild erythema
- Winlevi (clascoterone cream 1%) is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris by limiting sebum production and inflammation. It is expected to be available in the US in early 2021
Click here to read full press release/ article | Ref: PR Newswire | Image: PR Newswire